Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Annals of Oncology

• Publication date

  2000-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1008396414915PMID 11061621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

  2000cited by this paper
• Oral topotecan: bioavailability and effect of food co-administration

  1999cited by this paper
• Oral chemotherapy: rationale and future directions.

  1998cited by this paper
• Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.

  1998cited by this paper
• Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

  1998cited by this paper
• Patient preferences for oral versus intravenous palliative chemotherapy.

  1997cited by this paper
• Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

  1996cited by this paper

• Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

  2015cites this paper
• Body-Surface A rea-Based D osing D oes N ot I ncrease Accuracy o f P redicting C isplatin E xposure

  2013cites this paper
• Pharmacokinetics of novel anticancer drugs and dynamics of circulating tumor cells in early clinical studies

  2011cites this paper
• Population pharmacokinetics of cisplatin in adult cancer patients

  2004cites this paper
• Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.

  2002cites this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cites this paper
• Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

  2002cites this paper
• Pharmacologic aspects of new classes of anti-cancer agents: inhibitors of topoisomerase I or tubulin

  2001cites this paper
• Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

  2001cites this paper
• Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer

  2001cites this paper